SAFETY AND TOLERABILITY OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: INTEGRATED INTERIM ANALYSIS OF INFECTION RISK AND HEMATOLOGICAL CHANGES

被引：0
|
作者：
Muppidi, Srikanth
Pasnoor, Mamatha
Gelinas, Deborah
Brauer, Edward
Kerstens, Rene
Bhavaraju-Sanka, Ratna
Howard, James
机构：
来源：
MUSCLE & NERVE | 2022年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
193
引用
收藏
页码：S104 / S104
页数：1
相关论文
共 50 条
  • [21] A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients
    Pane, Chiara
    Di Stefano, Vincenzo
    Cuomo, Nunzia
    Sarnataro, Alessio
    Vinciguerra, Claudia
    Bevilacqua, Liliana
    Brighina, Filippo
    Rini, Nicasio
    Puorro, Giorgia
    Marsili, Angela
    Garibaldi, Matteo
    Fionda, Laura
    Sacca, Francesco
    JOURNAL OF NEUROLOGY, 2024, 271 (09) : 6209 - 6219
  • [22] A Real-life experience with Eculizumab and Efgartigimod in generalized Myasthenia Gravis patients
    Sacca, F.
    Cuomo, N.
    Russo, C.
    Campanile, M.
    Puorro, G.
    Marsili, A.
    Pane, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 569 - 569
  • [23] MINIMAL SYMPTOM EXPRESSION IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS FROM TREATMENT WITH EFGARTIGIMOD
    Howard, James
    Bril, Vera
    Vu, Tuan
    Karam, Chafic
    Pasnoor, Mamatha
    Muppidi, Srikanth
    Peric, Stojan
    Murai, Hiroyuki
    Guglietta, Antonio
    Ulrichts, Peter
    T'joen, Caroline
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    MUSCLE & NERVE, 2021, 64 : S3 - S4
  • [24] Safety and Effectiveness of Eculizumab for Patients with Generalized Myasthenia Gravis in Japan: Interim Analysis of Post-Marketing Surveillance
    Murai, H.
    Suzuki, S.
    Hasebe, M.
    Fukamizu, Y.
    Rodrigues, E.
    Utsugisawa, K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 485 - 486
  • [25] Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance
    Murai, Hiroyuki
    Suzuki, Shigeaki
    Hasebe, Miki
    Fukamizu, Yuji
    Rodrigues, Ema
    Utsugisawa, Kimiaki
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [26] Long-term Safety and Efficacy of Efgartigimod in Patients With Generalised Myasthenia Gravis
    Meisel, A.
    Bril, V.
    Vu, T.
    Karam, C.
    Peric, S.
    De Bleecker, J.
    Murai, H.
    Beydoun, S.
    Pasnoor, M.
    Guglietta, A.
    Ulrichts, P.
    T'joen, C.
    Utsugisawa, K.
    Verschuuren, J.
    Mantegazza, R.
    Howard, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 62 - 62
  • [27] Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT plus ): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
    Howard Jr, James F.
    Bril, Vera
    Vu, Tuan
    Karam, Chafic
    Peric, Stojan
    De Bleecker, Jan L.
    Murai, Hiroyuki
    Meisel, Andreas
    Beydoun, Said R.
    Pasnoor, Mamatha
    Guglietta, Antonio
    Van Hoorick, Benjamin
    Steeland, Sophie
    T'joen, Caroline
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    FRONTIERS IN NEUROLOGY, 2024, 14
  • [28] Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series
    Horiuchi, Kazuhiro
    Nakamura, Shuntaro
    Yamada, Kazuki
    Inoue, Takashi
    Oiwa, Kei
    NEUROMUSCULAR DISORDERS, 2024, 39 : 37 - 41
  • [29] A real-life experience with Eculizumab and Efgartigimod in generalized myasthenia gravis patients.
    Fionda, L.
    Pane, C.
    Di Stefano, V.
    Cuomo, N.
    Sarnataro, A.
    Vinciguerra, C.
    Bevilacqua, L.
    Brighina, F.
    Rini, N.
    Puorro, G.
    Marsili, A.
    Garibaldi, M.
    Sacca, F.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [30] Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis of shorter disease duration
    Genge, Angela
    Bril, Vera
    Vu, Tuan
    Brauer, Edward
    Kerstens, Rene
    Howard, James F., Jr.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
12345